1 / 54

Novel Protease Inhibitors for Hepatitis C

Novel Protease Inhibitors for Hepatitis C. Brittany Holt Kelly Kerr 4/30/09. Project Goals. Determine manufacturing and commercialization efforts, including the FDA approval process for a new orally available hepatitis C NS3/NS4A protease inhibitor (SCH 503034, Boceprevir)

brigid
Download Presentation

Novel Protease Inhibitors for Hepatitis C

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Novel Protease Inhibitors for Hepatitis C Brittany Holt Kelly Kerr 4/30/09

  2. Project Goals • Determine manufacturing and commercialization efforts, including the FDA approval process for a new orally available hepatitis C NS3/NS4A protease inhibitor (SCH 503034, Boceprevir) • Determine a novel molecule that can prevent the production and release of infectious HCV particles. • Predict the effectiveness of the new molecule. Compare this to the effectiveness of drugs that are currently being developed. • Modify molecules based on binding affinity tests

  3. HCV Background

  4. Hepatitis C: Background Information • 4.1 million Americans are affected • 150-200 million people worldwide • Genotype 1 is the most common genotype in America, Japan, and Europe • 10,000-12,000 Americans die annually • Current medications lead to a sustained virological response of only 40-50% among patients with Genotype 1 HCV • Current medications have many severe side effects

  5. HCV Life Cycle

  6. Viral Diversity Demands Drug Diversity • Potent drugs already on market • Dozens currently being evaluated So why another drug? • Multiple HCV strains • HCV inhibitors select for mutants

  7. Modeling versus Laboratory Research Study of actual virions is very difficult. • Lack of suitable cell cultures • Extremely small size • Trouble isolating virions from serum HCV proteins in databases!

  8. Target Selection Criteria Tool Available: Modeling Software Therefore we must select… • a viral protein • essential for virion production • that has a known active site for its function.

  9. Target: Adsorption • E1 and E2 • glycoproteins • associate with • cell surface • molecules • high variability

  10. Target: Endocytosis/Fusion/Uncoating Clathrin-coated pit: Entry Acidic endosomes: Fusion Uncoating: HCV RNA release

  11. Target: Translation RNA travels to the rough ER 5’NTR binds to ribosomal subunits & initiator tRNA creating the Translational active complex (HCV polyprotein synthesis)

  12. Target: Posttranslational Processing

  13. Target: Replication • NS4B • attaches to ER and • forms membranous • web • NS3 helicase • unwinds RNA • NS5B • replicates RNA • NS5A • ?

  14. Target: Assembly and Release • Viral components • Cellular factors • Lipid droplets • Precise mechanisms are not well understood

  15. NS3 Protease • NS3 protease is a viral protein • NS3P cleaves several essential proteins • NS4A, NS4B, NS5A, and NS5B • Active site: Catalytic triad • NS3 needs NS4A (another viral protein)

  16. Catalytic Triad Mechanism • Acylation • peptide bond is cleaved • ester linkage is formed between polyprotein carbonyl C and NS3 protease • Deacylation • ester linkage is hydrolized • enzyme is regenerated

  17. Acylation

  18. Deacylation

  19. Hydrogen bonding of Boceprevir to NS3/NS4A protease

  20. Manufacturing and Commercialization Solution Procedure

  21. FDA Clinical Trials • Investigational New Drug Application (IND) • Sponsors must show the FDA results of preclinical (animal) testing • Submit proposal for clinical trials • FDA decides on safety of proposed trials • Phase 1 • 20-80 volunteers • Goals: • Determine side effects • Determine how the drug is metabolized and excreted • Phase 2 • Evidence of safety must be shown • 20-300 patients with HCV • Goals: • Determine if the drug works on HCV • Compare the drug with a placebo or another medication • Evaluate safety • Study side effects • Phase 3 • Evidence of effectiveness must be shown • 200-3,000 patients with HCV • Goals: • Effectiveness in different populations • Dosage amounts • Effectiveness with other drugs

  22. Gantt Chart – Implementation of Boceprevir

  23. Gantt Chart Analysis • There is a competitive edge to producing the first drug that makes it through clinical trials • Gain reputation for safety and effectiveness • Retain a significant market share • Increased sales

  24. Synthesis of Boceprevir

  25. Alternate Pathways for Synthesis of Boceprevir

  26. Choosing Schemes to Model Schemes 1 and 4 were modeled in Super Pro Comparisons between 1, 2, & 3 were not made • Detailed instructions were given for the Scheme 1 • Can include every operation for Scheme 1 • Estimated batch times and costs for Schemes 2 and 3 would be unfairly low • Reagents used in Scheme 1 are more readily obtainable • Cost should be more accurate • Cost should be lower

  27. Production Goals • Tablets with 250 mg of active ingredient (SCH503034) • Roughly 7.5 million pills per year • Enough for 1% of HCV infected Americans to take once a day for 24 weeks • Minimal batch time • Reduce time equipment spends idle • Reduce losses that would occur if serious error

  28. Superpro Designer Modeling

  29. Super Pro - Flow Chart

  30. Super Pro - Flow Chart

  31. Gantt Chart – Processing Schedule (Synthesis of Boceprevir)

  32. Gantt Chart – Processing Schedule • One batch requires 149 hrs and over 200 operations • Effective batch time = 57.8 hrs • Use AOT schedule • Bottleneck is in Reactor 1 • Options for optimization • Make process continuous • Add a second R1

  33. Cost Estimates

  34. Histogram –Preclinical to Manufacturing Implementation and FCI

  35. Should development continue? • Money spent up to this point • $509,642,508 • Research and Development • Preclinical (Animal) Trials • Clinical Trials • Phase 1 • Phase 2 • Part of Phase 3

  36. Comparison with current medication costs

  37. Results • Development and Manufacturing will take approximately 14 years • The most likely total cost from research and development through plant construction will cost $528 million • This is less than the average cost for development of a drug, $802 million, as reported in the Journal of Health Economics • This cost is expensive, but relative to other drugs the cost of research and commercialization for boceprevir is reasonable • 1 month of current treatments: $4,225 • 1 month of boceprevir: $2553 with 1 year payback

  38. Predict new molecule that will work better than Boceprevir

  39. Selecting Molecules • Selection Criteria • Compare to Boceprevir • Ki • Inhibition constant: [L] at which ½ of the sites are occupied • Selectivity against human neutrophilelastase (HNE) • Ki (HNE)/ Ki (HCV) • Pharmacokinetics • Bioavailability: Fraction that reaches systemic circulation (4-11%) • AUC: Area under the concentration time curve (0.12 uMh )

  40. Solution Procedure

  41. Proposed Molecules

  42. NS3/NS4A Complex

  43. Binding of Drug to Protease

  44. Docking Server Ligands

  45. Docking Server Results

  46. Results • 16 potential drugs have been developed • All bind to catalytic triad • Potential drug #9 • Lower Ki • Higher HNE/HCV • We recommend that potential drug #9 be further evaluated using different docking software, and then be synthesized and undergo animal trials • We also recommend that further research continue on potential drugs 5, 7, 8, 10 and 15 • Increase selectivity • Keep high binding affinity

  47. Questions?

  48. Docking Server • molecular modeling internet service • developed by Virtua Drug Ltd • capable of calculating the site, geometry, and energy of molecules interacting with proteins

  49. Genetic algorithms • Genotype - translation, orientation, and conformation • Phenotype - atomic coordinates of the ligand • Fitness - total interaction energy of the ligand with the protein

  50. Genetic algorithms • Individuals that have low fitness die • New individuals are created by inheriting genes from either of two parents • Mutations also occur randomly • DockingServer can predict where and how a ligand will bind to be most energetically favorable

More Related